Company intelligence / Profile preview

Calypso Biotech

Amsterdam, North Holland, Netherlandscalypsobiotech.com ↗

Ownership: Private
Employees: ~11
Development stage: Phase 1

Overview

Calypso Biotech's lead product CALY-002 is a best-in-class anti-IL-15 antibody currently in Phase 1 trials. The company has completed the healthy volunteers phase showing favorable safety data and differentiating target engagement biomarker data. CALY-002 is the first IL-15-specific antibody to demonstrate blood NK cell reduction in humans. The company is on track for top-line histology data in Celiac Disease and Eosinophilic Esophagitis, and has shown proof-of-concept data in a humanized Atopic Dermatitis model.[6][3]

Therapeutic areas: GastroenterologyImmunologyDermatology
Modalities: Monoclonal antibodiesTherapeutic antibodies
Industry: Biotech

Drug pipeline

1 asset

CALY-002

Phase 1

Indications: Celiac disease, Eosinophilic esophagitis

Beyond the preview

Go deeper on Calypso Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calypso Biotech.

Explore the full profile